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LETTERS TO THE EDITORRegarding “Risk-adjusted 30-day outcomes of carotid
stenting and endarterectomy: Results from the SVS
Vascular Registry”
We read with interest the recent article by Sidawy et al regard-
ing 30-day outcomes between carotid artery stenting (CAS) and
endarterectomy from the Society for Vascular Surgery (SVS) vas-
cular registry.1 We believe there are two important perspectives
that materially affect the validity of these data and therefore the
conclusions.
First, the study documents that patients undergoing carotid
artery stenting were generally a high-risk group, characterized by the
greater prevalence of symptoms, diabetes, coronary artery disease,
prior myocardial infarction, congestive heart failure, COPD, prior
stroke, transient ischemic attack, peripheral vascular disease, GI ulcer,
and cardiac arrhythmias compared with the endarterectomy cohort.
Accordingly, it is not surprising the crude event rates are greater in the
CAS group. However, we disagree with the authors that the methods
used to achieve “best possible risk adjustment of these unmatched
groups” adequately take into consideration the marked differences
between these populations. The use of an automated algorithm such
as backwards elimination is generally inferior to regression models
based on a good understanding of the subject matter. Using the
current analytic approach, the authors have not shown that selection
bias, which likely accounts for much of the difference in outcomes
between the two groups, has been adequately accounted for. A
matched study design using a propensity score to more fully account
for selection bias may result in the comparison of groups with similar
baseline risks as opposed to the apples versus oranges comparison
presented.2,3 There are excellent contemporary examples of such
analysis in the literature.4 Reporting bias is also likely present given
that 30-day outcomes are only available for less than 50% of the full
cohort.5
Second, most CAS patients in this country undergo the pro-
cedure as part of a study or post-market surveillance registry which
require National Institutes of Health (NIH) stroke scale evaluation
by neurologist before and after the procedure. Most CEA done in
the clinical, non-study, environment do not have such evaluations,
and it has been shown that this will result in a significant underre-
porting of neurologic events (by a factor of 3).6 Since the distinc-
tion between major and minor stroke is not provided, we cannot
more clearly understand the influence of disparate neurologic
scoring.
Without adequately addressing these selection, reporting, and
outcome evaluation biases, it seems premature to make compari-
sons to lower risk patients undergoing carotid endarterectomy.
Somjot S. Brar, MD
William A. Gray, MD
Center for Interventional Vascular Therapy
Columbia University Medical Center
New York, NY
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Reply
The authors appreciate the comments from Dr Brar and Dr
Gray, who raise important issues regarding the rigor and validity of
the Vascular Registry (VR) data by comparing it with clinical trial
data. Most of the weaknesses discussed in Drs Brar and Gray’s
letter were identified as issues inherent to a study based on registry
data in the Discussion section of the manuscript.
With respect to selection bias, Drs Brar and Gray contend that
compared with the strict selection criteria of available clinical trial
data and post marketing registries, the VR results, which are based
on real-world use, are comparing apples (carotid artery stenting
[CAS]) to oranges (carotid endarterectomy [CEA]). It is true that
a great deal of selection bias can be introduced in a real-world
setting in which physicians are allowed to choose which procedure
better suits the best interest of the patient. By definition, patients
that receive CAS are going to be of a higher risk than patients who
receive CEA. Thus, because this is a current clinical practice
(real-world experience) registry, diversity in the patient population
is expected.
Drs Brar and Gray offer an interesting solution to reducing the
selection bias, a matched design using a propensity score analysis.
It should be noted that because the authors do have a good
understanding of the subject matter, logistic regression using
backwards elimination was used on the VR data instead of propen-
sity score matching, despite the fact that both methods demon-
strated that CAS patients have worse 30-day outcomes than CEA
patients. There are limitations to matching in two groups that are
highly incomparable as Drs Brar and Gray contend. If the two
groups do not have substantial overlap, then only the worst cases
from the CEA comparison are compared with only the best cases
from the CAS group, with the result being regression toward the
mean. Focusing on a select sub-group of patients, the matching
would eliminate a large number of patients and defeat the entire
purpose of conducting a current clinical practice registry. The goal
of the manuscript was to report the results of the entire VR, since
it is the first large scale registry that has available data on the current
practice application of CAS and CEA. Drs Brar and Gray wish to
make the VR data more similar to that of a clinical trial, but the
authors contend that there are already several clinical trials in which
these two procedures have been compared and few more still
ongoing. Having said the above and although the authors feel that
propensity score matching is not the most appropriate test in this
situation, the authors did apply it to the VR data and found that it
did not change the outcome.
With respect to reporting bias, Drs Brar and Gray also point
out that the Vascular Registry has poor 30-day follow-up. It was
noted in the manuscript that the VR does not have predefined visit
intervals and relies upon each facility’s standards of care in order to
capture the real-world experience. As noted in the manuscript, the
authors reported in-hospital and 30-day comparisons. The in-
hospital results were reported on 100% of patients; and even in this
comparison, the results have shown, in this registry, the superiority
of CEA.
